Correction to: Impact of new generation hormone-therapy on cognitive function in elderly patients treated for a metastatic prostate cancer: Cog-Pro trial protocol

Lange, Marie; Laviec, Heidi Solem; Castel, Hélène; Heutte, Natacha; Leconte, Alexandra; Léger, Isabelle; Giffard, Bénédicte; Capel, Aurélie; Dubois, Martine; Clarisse, Bénédicte; Coquan, Elodie; Fiore, Frédéric Di; Gouerant, S.; Philippe, Bartélémy,; Pierard, Laure; Fizazi, Karim; Joly, Florence

doi:10.1186/s12885-017-3764-9

Cited by 3 publications

(5 citation statements)

References 1 publication

(1 reference statement)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These treatments significantly improve the overall survival (OS) of patients with mCRPC before or after chemotherapy [ 14 , 17 , 18 , 19 ]. For now, in the absence of better mCRPC therapy, the relative efficacy associated with good tolerability profile of AAP and ENZ [ 20 ] tends to increase their availability to elderly patients [ 21 ]. Because aging by itself is associated with functional decline, this population of cancer patients appears at greater risk for increased age-related brain changes secondary to cancer and cancer treatments [ 22 ] impacting QoL.…”

Section: Introductionmentioning

confidence: 99%

“…Because aging by itself is associated with functional decline, this population of cancer patients appears at greater risk for increased age-related brain changes secondary to cancer and cancer treatments [ 22 ] impacting QoL. Interestingly, delayed health-related QoL alteration and pain progression was observed for ENZ or AA compared with chemotherapy [ 15 , 23 , 24 ], but their impact has never been evaluated in mCRPC patients on objective cognitive functions, despite a current clinical trial [ 21 ]. Recently, neurological events were described with ENZ [ 25 ], confirmed in a prospective phase IV study showing more fatigue and subjective cognitive impairments in ENZ- than in AAP-treated mCRPC patients [ 26 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Prostate Cancer Therapy Enzalutamide Compared with Abiraterone Acetate/Prednisone Impacts Motivation for Exploration, Spatial Learning and Alters Dopaminergic Transmission in Aged Castrated Mice

Nicola

Dubois

Campart

et al. 2021

Cancers

Self Cite

View full text Add to dashboard Cite

Cognitive side effects after cancer treatment threatening quality of life (QoL) constitute a major challenge in oncology. Abiraterone acetate plus prednisone (AAP) and enzalutamide (ENZ) are examples of next-generation therapy (NGT) administered to metastatic castration-resistant prostate cancer (mCRPC) patients. NGT significantly improved mCRPC overall survival but neurological side effects such as fatigue and cognitive impairment were reported. We developed a behavioral 17 months-aged and castrated mouse model receiving per os AAP or ENZ for 5 days per week for six consecutive weeks. ENZ exposure reduced spontaneous activity and exploratory behavior associated with a decreased tyrosine hydroxylase (TH)-dopaminergic activity in the substantia nigra pars compacta and the ventral tegmental area. A decrease in TH+-DA afferent fibers and Phospho-DARPP32-related dopaminergic neuronal activities in the striatum and the ventral hippocampus highlighted ENZ-induced dopaminergic regulation within the nigrostriatal and mesolimbocortical pathways. ENZ and AAP treatments did not substantially modify spatial learning and memory performances, but ENZ led to a thygmotaxis behavior impacting the cognitive score, and reduced c-fos-related activity of NeuN+-neurons in the dorsal hippocampus. The consequences of the mCRPC treatment ENZ on aged castrated mouse motivation to exploration and cognition should make reconsider management strategy of elderly prostate cancer patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The Prostate Cancer Therapy Enzalutamide Compared with Abiraterone Acetate/Prednisone Impacts Motivation for Exploration, Spatial Learning and Alters Dopaminergic Transmission in Aged Castrated Mice

Nicola

Dubois

Campart

et al. 2021

Cancers

Self Cite

View full text Add to dashboard Cite

show abstract

“…Because aging by itself is associated with functional decline, this population of cancer patients appears at greater risk for increased age-related brain changes secondary to cancer and cancer treatments impacting QoL (Lange et al, 2014). Interestingly, delayed health-related QoL alteration and pain progression was observed for ENZ or AA compared with chemotherapy (Khalaf et al, 2017;Shore et al, 2018), but their impact has never been evaluated in mCRPC patients on objective cognitive functions, despite a current clinical trial (Lange et al, 2018). Recently, neurological events were described with ENZ, confirmed in a prospective phase IV study showing more fatigue and subjective cognitive impairments in ENZ-than in AAP-treated mCRPC patients (Thiery-Vuillemin et al, 2020).…”

Section: Introductionmentioning

confidence: 99%

New generation prostate cancer therapy may impact motivation for exploration, spatial learning and dopaminergic transmission in aged castrated mice

Nicola,

Dubois,

Campart

et al. 2024

Preprint

View full text Add to dashboard Cite

Background and Purpose: Cognitive side effects after cancer treatment threatening quality of life (QoL) constitute a major challenge in oncology. Abiraterone acetate plus prednisone (AAP) and enzalutamide (ENZ) are next generation therapy (NGT) administered with androgen deprivation therapy to metastatic castration-resistant prostate cancer (mCRPC) patients. NGT significantly improved mCRPC overall survival but neurological side effects such as fatigue and cognitive impairment have been recently reported. Experimental Approach: We developed a behavioral 17 months-aged and castrated mouse model receiving per os AAP or ENZ during 5 days per week for six consecutive weeks. After behavioral tests, brain and plasma were collected for immunohistochemical studies. Spontaneous activity, cognitive functions and emotional reactivity, as well as neurobiological functions were investigated. Key Results: ENZ exposure reduced spontaneous activity and exploratory behavior associated with a decreased tyrosine hydroxylase (TH)-dopaminergic activity in the substantia nigra pars compacta and the ventral tegmental area. A decrease in TH+-DA afferent fibers and Phospho-DARPP32-related dopaminergic neuronal activities in the striatum and the ventral hippocampus, highlighted ENZ-induced dopaminergic regulation whithin the nigrostriatal and mesolimbocortical pathways. ENZ and AAP treatments did not substantially modify spatial learning and memory or behavioral flexibility performances, but ENZ led to a thygmotaxis behavior impacting the cognitive score, and reduced c-fos-related activity of NeuN+-neurons in the dorsal hippocampus. Conclusion and Implications: These results establish the consequences of the mCRPC treatment ENZ in aged castrated mouse motivation to exploration and cognition, of particular importance for future management of patients elderly postrate cancer patients and their QoL.

show abstract

“…These treatments significantly improve the overall survival (OS) of patients with mCRPC before or after chemotherapy (14,(17)(18)(19). For now, in the absence of better mCRPC therapy, the relative efficacy associated with good tolerability profile of AAP and ENZ (20) tends to increase their availability to elderly patients (21). Because aging by itself is associated with functional decline, this population of cancer patients appears at greater risk for increased agerelated brain changes secondary to cancer and cancer treatments (22) impacting QoL.…”

Section: Introductionmentioning

confidence: 99%

“…Because aging by itself is associated with functional decline, this population of cancer patients appears at greater risk for increased agerelated brain changes secondary to cancer and cancer treatments (22) impacting QoL. Interestingly, delayed health-related QoL alteration and pain progression was observed for ENZ or AA compared with chemotherapy (15,23,24), but their impact has never been evaluated in mCRPC patients on objective cognitive functions, despite a current clinical trial (21). Recently, neurological events were described with ENZ (25), confirmed in a prospective phase IV study showing more fatigue and subjective cognitive impairments in ENZ-than in AAP-treated mCRPC patients (26).…”

Section: Introductionmentioning

confidence: 99%

The prostate cancer therapy enzalutamide compared with abiraterone acetate/prednisone impacts motivation for exploration, spatial learning and alters dopaminergic transmission in aged castrated mice

Nicola

Dubois

Campart

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

Cognitive side effects after cancer treatment, threatening quality of life (QoL) and adherence to treatments, now constitute a major challenge in oncology. Abiraterone acetate plus prednisone (AAP) and enzalutamide (ENZ) are next generation therapy (NGT) administered with androgen deprivation therapy to metastatic castration-resistant prostate cancer (mCRPC) patients. NGT significantly improved mCRPC overall survival but neurological side effects such as fatigue and cognitive impairment have been recently reported. We developed a behavioral 17 months-aged and castrated mouse model receiving per os AAP or ENZ during 5 days per week for six consecutive weeks. After behavioral tests, brain and plasma were collected for immunohistochemical studies. The objective was to elucidate the impact of NGT on spontaneous activity, cognitive functions and emotional reactivity, as well as neurobiological functions. ENZ exposure reduced spontaneous activity and exploratory behavior associated with a decreased tyrosine hydroxylase (TH)-dopaminergic activity in the substantia nigra pars compacta and the ventral tegmental area. A decrease in TH+-DA afferent fibers and Phospho-DARPP32-related dopaminergic neuronal activities in the striatum and the ventral hippocampus, highlighted ENZ-induced dopaminergic regulation whithin the nigrostriatal and mesolimbocortical pathways. ENZ and AAP treatments did not substantially modify spatial learning and memory or behavioral flexibility performances, but ENZ led to a thygmotaxis behavior impacting the cognitive score, and reduced c-fos-related activity of NeuN+-neurons in the dorsal hippocampus. These results establish the consequences of the mCRPC treatment ENZ in aged castrated mouse motivation to exploration and cognition, of particular importance for future management of patients elderly postrate cancer patients and their QoL.

show abstract

Correction to: Impact of new generation hormone-therapy on cognitive function in elderly patients treated for a metastatic prostate cancer: Cog-Pro trial protocol

Cited by 3 publications

References 1 publication

The Prostate Cancer Therapy Enzalutamide Compared with Abiraterone Acetate/Prednisone Impacts Motivation for Exploration, Spatial Learning and Alters Dopaminergic Transmission in Aged Castrated Mice

The Prostate Cancer Therapy Enzalutamide Compared with Abiraterone Acetate/Prednisone Impacts Motivation for Exploration, Spatial Learning and Alters Dopaminergic Transmission in Aged Castrated Mice

New generation prostate cancer therapy may impact motivation for exploration, spatial learning and dopaminergic transmission in aged castrated mice

The prostate cancer therapy enzalutamide compared with abiraterone acetate/prednisone impacts motivation for exploration, spatial learning and alters dopaminergic transmission in aged castrated mice

Contact Info

Product

Resources

About